FINWIRES · TerminalLIVE
FINWIRES

Broadcom's AI Growth on Track, New Customers Likely to Ramp Deals, BofA Securities Says

By

Broadcom's (AVGO) fiscal Q2 results and Q3 guidance only modestly exceeded Street expectations, but its AI growth remains on track for about 180% year-over-year in fiscal 2026 and almost 100% in fiscal 2027, BofA Securities said in a note Thursday.

Broadcom's visibility in its AI compute program now extends into 2028, with multiple new customers, including Amazon-backed (AMZN) Anthropic, Meta (META), and Open AI expected to ramp purchase agreements over the next few years, according to the note.

The company's Software growth outlook of over 30% in fiscal Q3 suggests there are multiple growth vectors within the AI theme, the brokerage said, adding it expects earnings per share to exceed $30 by calendar year 2030, implying a compound annual EPS growth rate of about 40% between 2025 and 2030.

However, BofA flagged gross margin pressure as the custom chip mix continues to increase, noting that Broadcom is facing higher competition as clients diversify their suppliers and move away from exclusivity.

BofA Securities kept a buy rating on Broadcom and raised the price target to $530 from $450.

Shares of Broadcom were down 15% in Thursday trading.

Price: $407.18, Change: $-72.05, Percent Change: -15.03%

Related Articles

Wire

CrowdStrike Sees AI-Driven Demand Acceleration but Durability in Question, BofA Says

CrowdStrike's (CRWD) fiscal Q1 results and outlook showed strong execution, with the company seeing broad-based momentum and "clear step-ups" compared with last year, BofA Securities said in a note Thursday.The investment firm highlighted that CrowdStrike's fiscal Q1 net new annual recurring revenue of $256 million was up 32% year on year from $194 million in Q1, supporting total annual recurring revenue of $5.51 billion, an increase of 24% year on year. Meanwhile, Q1 revenue rose 26% to $1.39 billion and margins also expanded meaningfully, the note said.BofA said CrowdStrike's record Q2 pipeline, as well as strong retention of 97% gross and continued module adoption, support its guidance.The brokerage also noted that the company's management highlighted incremental AI-driven security spend, which is a shift from the previous year's consolidation-led growth.However, the key debate for CrowdStrike is now centered on sustainability, BofA said.The dynamics of the company's Falcon Flex product have accelerated meaningfully, with faster reflex timing at roughly 7 months and higher expansion uplift, raising questions on demand durability into the back half versus more linear expansion last year.BofA reiterated CrowdStrike's neutral rating and lifted the company's price target to $750 from $535.Shares of CrowdStrike were down nearly 8% in Thursday trading.Price: $689.08, Change: $-58.53, Percent Change: -7.83%

$CRWD
Wire

UnitedHealth's 'Favorable' Q2 Setup Driven by Improving Medical Cost Trends, BofA Says

UnitedHealth's (UNH) "favorable" Q2 earnings setup and attractive risk/reward are driven by improving medical cost trends and supportive near-term data points, BofA Securities said in a Thursday research report.BofA said it now expects EPS for 2026, 2027, and 2028 of $18.70, $21, and $24, respectively, from $18.30, $20.17, and $22.34 earlier.The company is guiding to the low-end of target margins by 2028, but even then, it would be well-positioned to grow earnings by at least 13% to 16% in the coming years, given that Optum Health and Medicaid would have room to lift margins back to the midpoint of target, analysts wrote.While the company's benefit cuts this year make it difficult to perform well, its contracts remain relatively diversified, according to the note.The brokerage said it upgraded the stock to buy from neutral and boosted its price target to $450 from $420.Price: $399.43, Change: $+22.43, Percent Change: +5.95%

$UNH
Wire

Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says

Erasca's (ERAS) early pan-RAS data have shifted the focus from whether ERAS-0015 is active to its potential commercial impact, with recent clinical results and stronger key opinion leader feedback strengthening confidence in the program's activity profile, BofA Securities said in a Thursday note.The analyst said ERAS-0015 has shown clinically meaningful activity across non-small cell lung cancer, pancreatic, and colorectal cancers, supporting Erasca's position in the competitive RAS-targeted therapy space, with safety appearing manageable so far but longer follow-up needed to confirm durability and survival benefit.BofA highlighted ERAS-4001 as a key pipeline opportunity in the second half of 2026 if it shows a broader therapeutic window and improved tolerability, while also citing colorectal cancer combinations and upcoming clinical readouts as near-term catalysts for sentiment and valuation.The outlook is now more balanced after early data, with upside from further efficacy confirmation, combinations, and readouts, while risks include durability, safety, competition, and uncertainty around differentiation and market path, the report added.BofA raised its rating on the stock to neutral from underperform and increased its price target to $16 from $9.Shares of Erasca were up 2.9% in Thursday trading.Price: $13.49, Change: $+0.31, Percent Change: +2.35%

$ERAS